150 related articles for article (PubMed ID: 22718449)
1. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: an introduction].
Feriozzi S
G Ital Nefrol; 2012; 29(3):267-73; discussion 292. PubMed ID: 22718449
[TBL] [Abstract][Full Text] [Related]
2. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
Cravedi P
G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy mechanisms in glomerulonephritis].
Polci R; Feriozzi S
G Ital Nefrol; 2011; 28(6):612-21. PubMed ID: 22167612
[TBL] [Abstract][Full Text] [Related]
4. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.
Manrique J; Cravedi P
Nefrologia; 2014 May; 34(3):388-97. PubMed ID: 24798567
[TBL] [Abstract][Full Text] [Related]
5. Update on the role of rituximab in kidney diseases and transplant.
Ramanath V; Nistala R; Chaudhary K
Expert Opin Biol Ther; 2012 Feb; 12(2):223-33. PubMed ID: 22188359
[TBL] [Abstract][Full Text] [Related]
6. The use of monoclonal antibodies in immune-mediated hematologic disorders.
Dierickx D; Beke E; Devos T; Delannoy A
Med Clin North Am; 2012 May; 96(3):583-619, xi. PubMed ID: 22703857
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal antibodies in nephrology: a delicate balance between curative potential, evidence of effectiveness, and toxicity].
Magistroni R
G Ital Nefrol; 2012; 29(3):283-91; discussion 292. PubMed ID: 22718451
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
[TBL] [Abstract][Full Text] [Related]
10. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
11. Immune-mediated hemolytic anemia in children after liver and small bowel transplantation.
Czubkowski P; Williams M; Bagia S; Kelly D; Gupte G
Liver Transpl; 2011 Aug; 17(8):921-4. PubMed ID: 21472974
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
13. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: emerging treatment strategies of immune-mediated glomerular disease.
Kattah AG; Fervenza FC
Expert Rev Clin Immunol; 2012 Jul; 8(5):413-21. PubMed ID: 22882216
[TBL] [Abstract][Full Text] [Related]
15. [Interleukin 10 in disseminated lupus erythematosus].
Emilie D
J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
[TBL] [Abstract][Full Text] [Related]
16. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
17. New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.
Dastiridou A; Kalogeropoulos C; Brazitikos P; Symeonidis C; Androudi S
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):543-55. PubMed ID: 23121277
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapy for B-cell malignancies.
Cheson BD
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S2-14. PubMed ID: 16720198
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic antibody: new opportunity for immunity and inflammatory diseases].
Sun W; Lin H; Hua F; Hu ZW
Yao Xue Xue Bao; 2012 Oct; 47(10):1306-16. PubMed ID: 23289142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
